Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
9 Meters Biopharma Inc
(NQ:
NMTR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 9 Meters Biopharma Inc
< Previous
1
2
3
Next >
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
March 23, 2022
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
March 21, 2022
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 09, 2022
RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
March 02, 2022
RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
February 28, 2022
RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
February 25, 2022
RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
Exposures
COVID-19
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
February 09, 2022
RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
January 24, 2022
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
January 18, 2022
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
January 04, 2022
RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
January 03, 2022
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
December 15, 2021
RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
November 15, 2021
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 - - Larazotide Phase 3 for celiac disease...
From
9 Meters Biopharma
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
November 10, 2021
- Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect - IND-enabling pathway...
From
9 Meters Biopharma
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
November 09, 2021
- In-Person Dates: November 16th-17th - Virtual Dates: November 18th-19th RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
October 26, 2021
- Vurolenatide's half-life is consistent with twice-monthly dosing - - Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE /...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
October 19, 2021
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
October 04, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
September 27, 2021
RALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating...
From
9 Meters Biopharma
Via
AccessWire
Topics
Hacking
Regulatory Compliance
Exposures
COVID-19
Information Security
Legal
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
September 22, 2021
- Conference Dates: September 27th-30th - RALEIGH, NC / ACCESSWIRE / September 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021
Conference Dates: September 20th-23rd RALEIGH, NC / ACCESSWIRE / September 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
- Conference Dates: September 13th-15th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 01, 2021
- Conference Dates: September 08th-10th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19
August 16, 2021
-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
August 12, 2021
- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"
August 05, 2021
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
July 19, 2021
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling...
From
9 Meters Biopharma
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
July 08, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
June 28, 2021
RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has...
From
9 Meters Biopharma
Via
AccessWire
Topics
Derivatives
Regulatory Compliance
Exposures
COVID-19
Derivatives
Legal
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
June 14, 2021
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9...
From
9 Meters Biopharma
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.